| Detailed information |
|---|
| CancerLivER ID | 2539 |
| Biomarker | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8, SOX4, |
| Biomarker Name/Symbol (given in Publication) | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7-L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8 and SOX4 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential pathological staging marker of HCC and upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change); but not validated on independent dataset |
| Experimental Condition | Intrahepatic metastasis v/s primary HCC and normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 18504433 |
| Type of Biomarker | Prognostic |
| Pathway | Adhesion molecules and Transcription factor |
| Cohort | Training dataset: 4 primary HCC (T1), 6 intrahepatic metastatic HCC (T3) and 2 normal liver samples (HNL); validation dataset : T3 tumors (n=24) /higher than adjacent normal tissues (n=61, adjacent-average) and T1 tumors (n=15). |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Intrahepatic metastasis v/s primary HCC and normal |
| Year of Publication | 2008 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |